Issue link: http://www.e-digitaleditions.com/i/853645
Inhalation August 2017 15 22. Lin HL, Wan GH, Chen YH, Fink JB, Liu WQ, Liu KY. Influence of nebulizer type with different pedi- atric aerosol masks on drug deposition in a model of a spontaneously breathing small child. Respir Care. 2012; 57(11):1894-1900. 23. Lin HL, Harwood RJ, Fink JB, Goodfellow LT, Ari A. In vitro comparison of aerosol delivery using differ- ent face masks and flow rates with a high-flow humidity system. Respir Care. 2015; 60(9):1215-1219. 24. Miller NC. Apparatus and process for aerosol size measurement at varying gas flow rates. US Patent 6,435,004-B1, 2002. 25. Olsson, B, Borgström L, Lundbäck, H, Svensson M. Validation of a general in vitro approach for predic- tion of total lung deposition in healthy adults. J. Aerosol Med Pulmon Drug Deliv. 2013; 26(6):355-369. 26. Morton, RW, Mitchell JP. Design of facemasks for delivery of aerosol-based medication via pressurized metered dose inhaler (pMDI) with valved holding chamber (VHC): Key issues that affect performance. J Aerosol Med. 2007; 20(S1):S29-S45. 27. Smaldone GC, Berg E, Nikander K. Variation in pediatric aerosol delivery: Importance of facemask. J Aerosol Med. 2005; 18:354-363. 28. Kraemer R, Frey U, Sommer CW, Russi E. Short- term effect of albuterol, delivered via a new auxiliary device in wheezy infants. Am Rev Respir Dis. 1991; 144:347-351. 29. Mitchell JP. Appropriate face models for evaluating drug delivery in infants and small children: e current situation and prospects for future advances. J. Aerosol Med, 2008; 21(1):97-111. 30. Carrigy NB, O'Reilly C, Schmitt J, Noga M, Fin- lay WH. Effect of facial material softness and applied force on face mask dead volume, face mask seal, and inhaled corticosteroid delivery through an idealized infant replica. J Aerosol Med Pulmon Deliv. 2014; 27(4):290-298. 31. Nagel M, Suggett J, Mitchell JP. Development and evaluation of a family of human face and upper airway models for the laboratory testing of orally inhaled prod- ucts. AAPS PharmSciTech. 2017;18. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28536796. Accessed June 25, 2017. 32. Shah SA, Berlinski AB, Rubin BK. Force-depen- dent static dead space of face masks used with holding chambers. Respir Care. 2006; 51(2):140-144. 33. Amirav I, Halamish A, Gorenberg M, Omar H, Newhouse MT. More realistic face model surface improves relevance of pediatric in-vitro aerosol studies. PLoS One, 2015;10(6): e0128538. Available at: https://www.ncbi.nlm.nih.gov/pmc/ar ticles/ PMC4474798/pdf/pone.0128538.pdf. Accessed May 5, 2017. 34. Hess DR. Nebulizers—Principles and perfor- mance. Respir Care. 2000; 45(6):609-622. 35. Mansour KS. Technical Bulletin—AirLife ® Misty Fast TM disposable small-volume nebulizer. July 2013. Available at: http://www.carefusion.com/Documents/ technical-bulletins/RC_Misty-Fast-Bulletin_TB_ EN.pdf. Accessed May 6, 2017. 36. Dennis JH. A review of issues relating to nebulizer standards. J Aerosol Med. 1998; 11(S1):S73-S79. 37. Tandon R, McPeck M, Smaldone GC. Measuring nebulizer output: Aerosol production vs gravimetric analysis. Chest. 1997; 111(5):1361-1365. 38. PARI Technical Bulletin: PARI JuniorBoy® SX— Inhalation therapy for the needs of infants and children. Available at: https://www.pari.com/fileadmin/user_ upload/PARI.com_DE/Doc/de/Docs/085D0097- EN-PARI-Inhalation-therapy-for-the-needs-of-ba bies-and-infants.pdf. Accessed May 6, 2017. 39. Chatburn RL, McPeck M. A new system for under- standing nebulizer performance. Respir Care. 2007; 52(8):1037-1050. 40. Westmed Inc. Westmed presents FIA: Fraction of inhalable aerosol. 2012. Available at: http://westmed inc.com/wp-content/uploads/2015/02/FIA-Single- Sheet-Flyer.pdf. Accessed May 8, 2017. 41. Wee WB, Leung K, Coates AL. Modeling breath-enhanced jet nebulizers to estimate pulmonary drug deposition. J Aerosol Med Pulmon Drug Deliv. 2013; 26(6):387-396. 42. Ari A. Jet, ultrasonic, and mesh nebulizers: An eval- uation of nebulizers for better clinical outcomes. Eur- asian J Pulmonol. 2014; 16(1):1-7. Jolyon P. Mitchell, PhD, FRSC(UK), CChem, CSci is an Adjunct Professor at the University of Western Ontario, an Affiliate Professor at University of Hawaii and the CEO of Jolyon Mitchell Inhaler Consulting Services, Inc. Mark W. Nagel (HBSc) is Head of Aerosol Science at Trudell Medi- cal International, London, Ontario, Canada. Jason A. Suggett (BPharm, PhD, MBA ) is Group Director Science and Technology at Trudell Medical International, London, Ontario, Canada. Dominic P. Coppolo (MBA, RRT, FAARC ) is Vice President Clinical Strategy and Develop- ment) at Monaghan Medical Corporation, Syracuse, NY, US. Corresponding author: Jolyon P. Mitchell, Jolyon Mitchell Inhaler Consulting Services, Inc., 1154 St. Anthony Road, London, Ontario, N6H 2R1, Canada, +1 519 472-5364, mitchelljolyon@gmail.com. To read the first article in this series "Obscuring the message: A critical examination of laboratory test methods for orally inhaled products that could lead the user astray: Part 1—Aerodynamic Particle Size Distribution (APSD)," please visit the Inhalation home page or article archive.